Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) just unveiled an announcement.
IRLAB Therapeutics AB has announced an 85% secured rights issue to raise approximately SEK 136 million, with an extended debt financing of SEK 30 million. The funds will support business development and the advancement of drug candidates, strengthening the company’s financial position and enhancing its appeal in partnership discussions.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a biotechnology company focused on developing novel treatments for Parkinson’s disease. The company is engaged in clinical and preclinical development of drug candidates aimed at enhancing their commercial appeal and securing revenue-generating partnerships.
Average Trading Volume: 36,430
Current Market Cap: SEK351.7M
See more data about IRLAB.A stock on TipRanks’ Stock Analysis page.